BASILEA N | 38,350 / 0,00% |
日期/時間 | 06.07. / 17:31 |
漲跌。 / 漲跌。(%) | 0,000 / 0,00% |
Bid | 38,000 / 100 |
Ask | 39,000 / 1300 |
打開 | 38,900 |
過往收市 | 38,350 |
高 | 39,300 |
低 | 38,000 |
成交量 [CHF] | 1.135.691,750 |
成交量 [Units] | 29.555 |
Price fixings | 318 |
ISIN | CH0011432447 |
符號 | BSLN |
交易所 | SIX Swiss Exchange |
類型 | 股票 |
交易所 | 最後的 | 成交量 | |
---|---|---|---|
SIX Swiss Ex.. | 38,350 | ![]() |
29.555 |
Cboe Europe .. | 38,40 | ![]() |
2.648 |
London Domes.. | 38,35 | ![]() |
2.648 |
Cboe Europe .. | 38,40 | ![]() |
1.765 |
Turquoise | 38,35 | ![]() |
1.056 |
Lang & Schwa.. | 38,65 | ![]() |
|
Nasdaq Other.. | 41,0000 | 40 | |
München | 32,300 | 0 | |
Berlin | 32,100 | 0 | |
Frankfurt | 32,2800 | 0 | |
gettex | 32,340 | ||
TradeGate | 30,300 | 33 | |
EUREX | Options |
新聞
- Basilea reports preclinical data on anti-cancer activity of novel oncology drug candidate BAL0891 at ESMO TAT congress
08.03.2022 / 07:15 - GlobeNewswire - Basilea to become a leading anti-infectives company backed by strong financial results 2021
15.02.2022 / 07:15 - GlobeNewswire - Basilea reports updated interim results for iCCA patients with FGFR2 mutations and amplifications from phase 2 study FIDES-01 at ASCO GI Cancers Symposium
24.01.2022 / 07:15 - GlobeNewswire - Basilea announces approval of antifungal Cresemba® (isavuconazole) for invasive aspergillosis in China
13.01.2022 / 07:15 - GlobeNewswire - Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigating ceftobiprole in bloodstream infections
11.01.2022 / 07:15 - GlobeNewswire